The Dow Jones, Nasdaq 100 and S&P 500 indexes recovered from Monday’s losses. These three indices grew to nearly $40,000 each, and $5,345 for the Nasdaq 100.
Investors predicted the Federal Reserve would start cutting rates in the near future, and this rebound occurred as fears faded of the Japanese carry trade . The recent earnings season was also very successful. In fact, S&P 500 companies’ revenue grew by 10.8%.
David Kostin, an analyst at Goldman Sachs believes some stocks are undervalued. They could make a quick comeback. The list includes names like Micron Technology (formerly Toast), Williams-Sonoma, Pfizer and Williams-Sonoma, as well as Carnival Corporation.
CCL
The stock of Carnival Corporation (CCL), meanwhile, is experiencing a tough year despite the recovery in the cruise industry. Royal Caribbean’s share price has increased by more than 20%, while its stock is down by 20%.
Carnival is doing well, as its latest results show. Its net income increased by $500,000,000 to $92,000,000. The company’s operating profit jumped from $560 to more than $1.2 billion.
Carnival also has received significant bookings over the last few months. Recent data shows that they have reached record numbers of 2025 sailings. Bookings for next year and their prices will be higher than the highs of this year.
Carnival has also increased its guidance for next year and anticipates a 10.25% increase in net yields. The company is also speeding up its transformation by aiming to close down P&O Cruises Australia. This will allow it to add new ships to the Carnival Cruise Line Fleet.
MU
Goldman Sachs believes the Micron Technology share price is also more likely to rise now that its stock has fallen by over 40% since its peak this year, and hovers at its lowest level since March of last year.
Micron’s performance is similar to that of companies such as Nvidia (NVDA), Intel (AMD), and Applied Materials (AMAT). All have recently retreated due to concerns over growth and a softening AI market.
Micron’s latest earnings revealed that the company had increased its revenues to $6.81 Billion in the third fiscal quarter. This is higher than $5.82 Billion it earned in the same time period last year. The net profit grew to more than $332 million. Micron anticipates revenue of $7.6 billion for the current quarter.
Goldman Sachs predicts that semiconductor demand will increase in coming months, and that this is likely to lead to a recovery of the shares.
TOAST
Toast is a fintech company that ranks among the largest in the United States. The company is a payment processor for restaurants and hotels. They can choose from a variety of solutions, including a point-of sale solution, self-ordering kiosks, rota-management software, gift cards, etc.
Toast provides its solutions to a large number of US restaurants, including BANG, Sweetgreen Jamba and Barteca Restaurant Group. And Dos Toros Taqueria.
Toast has seen its business grow rapidly over the last few years. Its annual revenue has increased from $665m to $3.86bn by 2023. The company’s growth in revenue has been sustained this year, as it added over 8,000 new locations during the second quarter.
Toast increased its revenue to $1.24billion in Q2 compared with $978m in the previous quarter. The company also went from $98 million in losses to over $14 million. Goldman Sachs thinks that Toast’s stock is still worth more than it was at its peak this year.
Pfizer | PFE
Pfizer’s stock has suffered a lot of pressure over the last few years. It went from reaching a high of $54.73 on December 20, 2021, to hitting a low price of $24.56 in early this year.
The company was unable to maintain its record profits and revenues during the pandemic. The company’s revenues increased from $41billion in 2020 to more than $81billion and then $100billion in 2021.
Last year, the figure dropped to 58.4 Billion dollars. Even worse, it has made a loss of $2.1 billion in the past twelve months. Pfizer missed out on the weight-loss trend, as well. Its product imploded in 2023. Recently, it returned to the weight-loss sector but it’s unclear if it will be successful.
The company hopes that a number of its acquisitions will be able to help the business succeed. In 2023, it spent more than $43 billion to acquire Seagen, which focuses on antibodies as cancer treatment.
Watch here: https://www.youtube.com/embed/VL-vOQTBq3w?feature=oembed
Pfizer had previously spent $5 billion on Anacor Pharmaceuticals and another $11.4 billion to purchase Array BioPharma. It also invested $14 billion into Medivation as well as $17 billion for Hospira. Goldman Sachs believes that Pfizer’s stock will eventually recover despite its recent woes.
The post Goldman Sachs Buy Carnival, Micron and Toast Stocks may change as new information becomes available.
